Biofrontera Inc.

Welcome to the BioFrontera Inc. 4th Quarter and Full Year 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the Start button. After today's prepared remarks, there will be an opportunity to ask questions. To ask questions, you may press Start, then 1 on your telephone keypad. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Turg Patel with LHA Investor Relations. Please go ahead.

Good morning, and welcome to BioPrantera Inc.' 's fourth quarter and full year 2021 financial results conference call. Please note that certain information discussed during today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that Biofront Tariffs Management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in BioProntera's press releases and SEC filings. This conference call contains time-consumed information that is accurate only as of the date of the live broadcast today, April 8, 2022. BioProntera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non-GAAP financial measures. BioProntera believes these measures provide useful information for investors, yet should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in this morning's press release. With that, I would like to turn the call over to Herman Loubert, Executive Chairman of BioProntera, Inc.

Thank you, Toast. and welcome everyone to BioFrontera Inc's 2021 Fourth Quarter and Full Year Financial Results Conference call. Joining me today is Erika Monaco, Chief Executive Officer of BioFrontera Inc. In a moment, Erika will review the business, our strategy, and our recent financial results. But first, I would like to provide a brief recap of our achievements during 2021. The global dermatology market, and specifically the photodynamic therapy market, experienced encouraging growth following a year of depressed numbers of patient visits to dermatologists during the height of the COVID-19 pandemic. In the United States, which is the world's largest dermatology market, we have likewise experienced a consistently growing rebound from those pandemic lows due to the management's commercial initiatives the lifting of some government restrictions and the reopening of our customers businesses our revenue recovered quickly beginning in in about march of 2021 i'm proud of the work of biofrontera's management sales teams and support staff in making 2021 a strong first year for BioFrontera following our successful IPO last fall. Sales for 2021 exceeded $24 million, were up about 28% versus 2020, and are approaching pre-pandemic levels. Earlier this week, we also announced very strong Over 100% year-over-year got sales growth for the first quarter of 2022, which further demonstrates that our business is back on track. With that, I'll turn the call over to Erica.